Compare Adaptive Biotechnologies Corp (ADPT) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Quantum Computing Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Quantum Computing Inc trades at $8.84 (market cap $1.96B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | QUBT | |
|---|---|---|
Market Cap | $3.33B | $1.96B |
Sector | Health | Technology |
52-Week High | $22.37 | $24.62 |
52-Week Low | $10.24 | $6.31 |
Enterprise Value | $3.19B | $977.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
QUBT trades at $9.37, up 3.54% today, but technical indicators signal a bearish trend with support at $9. The company shows minimal revenue of $682K in 2025 with a net loss of $18.67M, resulting in negative margins. Recent acquisitions and a potential $10M deal with Planck Dynamics highlight growth efforts, but cash burn remains high. Analyst consensus is bullish with a $24 price target, citing commercialization potential in quantum photonics.
The outlook hinges on QUBT's ability to scale revenue and manage cash burn amid intense quantum computing competition. While analyst optimism and policy tailwinds offer upside, high valuation multiples and persistent losses pose significant risks. Investors should weigh the long-term potential against near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
